Ibrutinib Capsules 140mg
IBRULIEVA contains Ibrutinib, a first-generation Bruton’s Tyrosine Kinase (BTK) inhibitor. It blocks BTK signaling in B-cells, thereby inhibiting the growth and survival of malignant B-lymphocytes.
View Details
Melphalan Tablet IP 2mg
MELIEVA contains Melphalan, an alkylating anticancer agent. It works by cross-linking DNA strands, thereby inhibiting DNA and RNA synthesis and leading to the death of rapidly dividing cancer cells.
View Details
Acalabrutinib Capsules 100mg
ACALIEVA contains Acalabrutinib, a second-generation Bruton’s Tyrosine Kinase (BTK) inhibitor. It works by blocking BTK signaling in B-cells, thereby inhibiting the growth and survival of malignant B-lymphocytes.
View Details
Hydroxyurea Capsules IP 500mg
HYDLIEVA contains Hydroxyurea, an oral antineoplastic agent. It works by inhibiting ribonucleotide reductase, which interferes with DNA synthesis, slowing or stopping the growth of rapidly dividing cancer cells.
View Details
Imatinib Mesylate Tablets IP 400mg
IMALIEVA contains Imatinib Mesylate, a targeted anticancer medicine. It works as a tyrosine kinase inhibitor (TKI) by blocking enzymes (BCR-ABL, c-KIT, PDGFR) that signal cancer cell growth, thereby slowing or stopping cancer progression.
View Details
Azacitidine for Injection 100MG
AZALIEVA 100 mg contains Azacitidine, a hypomethylating agent and pyrimidine nucleoside analogue. It incorporates into DNA and RNA, leading to inhibition of DNA methyltransferase, reactivation of tumor suppressor genes, and normalization of bone marrow function. It is mainly used in myelodysplastic syndromes (MDS).
View Details
Plerixafor Injection 24mg
MOZOLIEVA 24 mg contains Plerixafor, a hematopoietic stem cell mobilizer. It is a CXCR4 chemokine receptor antagonist that disrupts the interaction between CXCR4 and SDF-1α, causing rapid release of CD34+ stem cells from the bone marrow into peripheral blood for collection.
View Details
Fludarabine Phosphate for Injection 50mg
FLULIEVA 50 mg contains Fludarabine Phosphate, a purine nucleoside analogue antimetabolite. It is intracellularly converted to fludarabine triphosphate, which inhibits DNA polymerase, ribonucleotide reductase, and DNA primase, leading to suppression of DNA synthesis and apoptosis. It is widely used in hematologic malignancies.
View Details
Methotrexate Injection 500mg
TREXLIEVA 500 mg contains Methotrexate, an antimetabolite and antifolate chemotherapeutic agent. It inhibits dihydrofolate reductase (DHFR), blocking folate metabolism and DNA synthesis in rapidly dividing cells. This strength is commonly used in high-dose methotrexate (HD-MTX) oncology protocols.
View Details
Methotrexate Injection IP 50mg
TREXLIEVA 50 mg contains Methotrexate, an antimetabolite and antifolate chemotherapeutic agent. It inhibits dihydrofolate reductase (DHFR), leading to reduced DNA synthesis and cell replication, particularly in rapidly dividing cells. It is widely used in oncology, autoimmune diseases, and medical oncology protocols.
View Details
Bortezomib Injection IP 3.5mg
BORTLIEVA contains Bortezomib, a proteasome inhibitor used in cancer treatment. It works by blocking proteasomes in cells, leading to accumulation of proteins and apoptosis (cell death) of cancer cells.
View Details
Bortezomib Injection IP 2mg
BORTLIEVA 2 mg contains Bortezomib, a reversible proteasome inhibitor that inhibits the 26S proteasome. This leads to accumulation of misfolded proteins, disruption of cellular homeostasis, and apoptosis of malignant plasma cells. It is a key drug in multiple myeloma therapy.
View Details
